S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:ARDX

Ardelyx (ARDX) Stock Forecast, Price & News

$0.65
-0.02 (-2.97%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.62
$0.69
50-Day Range
$0.58
$1.17
52-Week Range
$0.58
$2.15
Volume
1.44 million shs
Average Volume
4.59 million shs
Market Capitalization
$94.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.84
30 days | 90 days | 365 days | Advanced Chart
Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx logo

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Headlines

Ardelyx (NASDAQ:ARDX) Price Target Cut to $3.00
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
N/A

Sales & Book Value

Annual Sales
$10.10 million
Book Value
$0.44 per share

Profitability

Net Income
$-158.16 million
Net Margins
-3,843.36%
Pretax Margin
-3,843.23%

Debt

Price-To-Earnings

Miscellaneous

Free Float
135,995,000
Market Cap
$94.45 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/22/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

746th out of 1,416 stocks

Pharmaceutical Preparations Industry

359th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx
or view top-rated stocks.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in April. As of April 30th, there was short interest totaling 11,540,000 shares, an increase of 20.0% from the April 15th total of 9,620,000 shares. Based on an average daily volume of 3,620,000 shares, the days-to-cover ratio is currently 3.2 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Ardelyx
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. Ardelyx had a negative net margin of 3,843.36% and a negative trailing twelve-month return on equity of 177.07%. During the same quarter last year, the business posted ($0.34) earnings per share.
View Ardelyx's earnings history
.

What price target have analysts set for ARDX?

7 equities research analysts have issued 12-month price objectives for Ardelyx's stock. Their forecasts range from $1.00 to $13.00. On average, they anticipate Ardelyx's share price to reach $5.24 in the next year. This suggests a possible upside of 702.6% from the stock's current price.
View analysts' price targets for Ardelyx
or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?
Ardelyx's management team includes the following people:
What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.94%), Great Point Partners LLC (3.29%), Vanguard Group Inc. (2.72%), AIGH Capital Management LLC (2.15%), State Street Corp (1.47%) and Pekin Hardy Strauss Inc. (1.20%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx
.

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Group One Trading L.P., Quantbot Technologies LP, Dimensional Fund Advisors LP, Magnus Financial Group LLC, and Simplex Trading LLC. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Michael Raab, Robert Blanks, and Scott D Sandell.
View insider buying and selling activity for Ardelyx
or view top insider-selling stocks.

Which major investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, AIGH Capital Management LLC, GSA Capital Partners LLP, Bank of New York Mellon Corp, Pekin Hardy Strauss Inc., Worth Venture Partners LLC, State Street Corp, and Orchard Capital Managment LLC.
View insider buying and selling activity for Ardelyx
or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $0.65.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $94.45 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158.16 million in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 86 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at [email protected], or via fax at 510-745-0493.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.